Jade Biosciences accelerates JADE101 Phase 3 trial start to fourth quarter 2026

• Jade Biosciences expects to initiate its EVERGREEN Phase 3 trial of JADE101 for IgA nephropathy ahead of schedule in fourth-quarter 2026.
• Interim data from the ongoing JUNIPER Phase 2 trial are now expected in second-quarter 2027.
• Study-design posters will be presented October 24, 2026, at ASN Kidney Week in Denver.
• A model-based assessment scheduled for October 22 will inform dose selection, assess anticipated responses to APRIL inhibition and support accelerated development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210700PRIMZONEFULLFEED9849878) on October 21, 2026, and is solely responsible for the information contained therein.